Allievex is a clinical-stage biotechnology company developing novel therapies for the treatment of rare pediatric neurodegenerative diseases. Its lead product candidate is tralesinidase alfa, an investigational enzyme replacement therapy for children with Sanfilippo syndrome type B or mucopolysaccharidosis IIIB (MPS IIIB).